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Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life threatening complication
that can develop after hematopoietic cell transplantation. Although SOS/VOD progressively resolves within a few weeks in most
patients, the most severe forms result in multi-organ dysfunction and are associated with a high mortality rate (480%). Therefore,
careful attention must be paid to allow an early detection of SOS/VOD, particularly as drugs have now proven to be effective and
licensed for its treatment. Unfortunately, current criteria lack sensitivity and speciﬁcity, making early identiﬁcation and severity
assessment of SOS/VOD difﬁcult. The aim of this work is to propose a new deﬁnition for diagnosis, and a severity-grading system for
SOS/VOD in adult patients, on behalf of the European Society for Blood and Marrow Transplantation.
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INTRODUCTION
Sinusoidal obstruction syndrome (SOS), also known as
veno-occlusive disease (VOD; referred to as SOS/VOD hereafter)
remains a potentially devastating complication after hematopoie-
tic cell transplantation (HCT).1 Toxic metabolites generated by the
conditioning regimen damage the sinusoidal endothelial cells and
hepatocytes in zone 3 of the hepatic acinus.2 Therefore, activated
sinusoidal endothelial cells round up, favoring the appearance of
gaps in the sinusoidal barrier. RBC, leukocytes and cellular debris
pass through these gaps into the space of Disse beneath the
endothelial cells, and dissect the endothelial lining. The venous
lumen progressively narrows and sinusoidal venous outﬂow is
reduced, resulting in post-sinusoidal portal hypertension.1 This
pathophysiological process leads to the clinical syndrome of
SOS /VOD, consisting of weight gain, ﬂuid retention with ascites,
painful hepatomegaly, jaundice and, in severe cases, multi-organ
dysfunction (also known as multi-organ failure, thereafter referred
as MOD/MOF), characterized by pulmonary and renal dysfunction,
as well as encephalopathy.1,3–5 SOS/VOD usually develops within
3 weeks after HCT, although in 15–20% it can occur later.6,7
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The incidence of SOS/VOD varies with the intensity of the
conditioning regimen, the type of transplant and the presence of
risk factors, but also with the clinical criteria used for SOS/VOD
diagnosis. At present, the incidence is ~ 10–15% after allogeneic
HCT (allo-HCT) conditioned with a myeloablative conditioning
(MAC) regimen, against o5% after autologous HCT and
allo-HCT conditioned with reduced intensity/toxicity conditioning
regimen.1,5,8–10 Although the SOS/VOD progressively resolves
within a few weeks in most patients, the most severe forms result
in MOD/MOF, and are associated with a high mortality rate
(480%).5,11 For this reason, despite the relatively low incidence of
this complication, early detection of SOS/VOD should be a priority,
particularly now that a new drug, deﬁbrotide, has proven to be
effective for its prevention and treatment.11–15 Unfortunately,
current criteria lack sensitivity and speciﬁcity, making early
identiﬁcation of SOS/VOD difﬁcult. The aim of this work is to
propose a new deﬁnition for SOS/VOD diagnosis and severity in
adult patients, on behalf of the European Society for Blood and
Marrow Transplantation (EBMT).
RATIONALE FOR THE NEW DIAGNOSTIC CRITERIA
Currently, two conﬂicting deﬁnitions of SOS/VOD coexist, based
on the Seattle criteria, reported by McDonald in 1984,3 and the
Baltimore criteria, reported by Jones in 1987.4 With minor
clariﬁcations/modiﬁcations,15–17 these criteria have been used in
clinical practice, as well as in research studies and trials, in the past
three decades.11,15 According to a recent meta-analysis, the
SOS/VOD incidence varied according to the criteria used between
17.3% (Seattle) and 9.6% (Baltimore).5 One of the major difﬁculties
is that, unlike some other transplant-related complications,
SOS/VOD is very dynamic in its manifestations, and the exact
deﬁnition is hard to establish; the diagnosis of severe forms
needs overt clinical manifestations, MOD/MOF and serious organ
damage, such as severe pulmonary or renal dysfunction and
encephalopathy, before the diagnosis can be made.
This conundrum has resulted in patients not getting early
therapy to prevent MOD/MOF, and has prevented attempts to
treat at a stage when the disease is in a more favorable response
state. The current criteria were acceptable in an era when the
available treatment was restricted and carried substantial toxic
effects, and early intervention did not elicit any apparent clinical
beneﬁt.18–21 However, they can no longer be justiﬁed, because
treatment options are available, and data show that early
intervention is justiﬁable and effective.11 Moreover, the develop-
ment of alternative donors and reduced intensity/toxicity
regimens22 led to a change in the natural history of HCT, and
increased frequency of late onset SOS/VOD, an observation that
should be taken into account for revised diagnostic criteria.
Likewise, new risk factors, related to these changes of HCT
practice, have been identiﬁed and should be taken into account
for prognosis assessment. Similarly, advances in imaging techni-
ques may call for an update on the speciﬁc variables that should
be used for diagnosis and prognosis assessment.23 Finally, while
current SOS/VOD deﬁnitions apply to both adults and children, the
clinical presentation of this complication differs between these
two patient populations. Thus, while most of adult patients have
hyperbilirubinemia,24 the incidence of SOS/VOD (including its
severe form) without hyperbilirubinemia in children is ~ 30%.15
Therefore, a proposal for distinct diagnostic criteria for adults and
children seems to be mandatory. This paper focuses on adult
patients; diagnostic criteria for children will be developed in
another article.
SOS/VOD RISK FACTORS
To intervene before the development of end-organ damage and
MOD/MOF in SOS/VOD, there is a need for accurate identiﬁcation
of risk factors and biomarkers to identify the subset of patients
with a likely severe form of the disease and at imminent risk of
deteriorating. There are three different kinds of SOS/VOD risk
factors: those directly related to the transplant; those related
to the patient's characteristics and underlying disease; and
hepatic-related risk factors (Table 1).
Transplant-related risk factors
These are directly related to the choice of the intensity of the
conditioning regimen, the type of donor and HLA-matching or the
GvHD prophylaxis. Given alloreactivity contributes to endothelial
damage and SOS/VOD pathophysiology, the risk of SOS/VOD
increases with the alloreactivity level. It is higher after allo-HCT as
compared with autologous HCT.5,8 However, allo-HCT by itself can
no longer be considered as a risk factor. Rather, only situations
where the alloreactivity of the transplant is increased, such as with
the use of an unrelated or an HLA-mismatched donor, and a non
T-cell-depleted graft should be considered as risk factors.25,26 Of
note HLA-haploidentical familial donors are increasingly used27
and while no study speciﬁcally address the risk of SOS/VOD in this
setting, we suggest that the use of a haploidentical donor could
be considered as a risk factor as any HLA-mismatched donor.
The risk of SOS/VOD onset also depends on the conditioning
regimen intensity and the drugs used. It is higher after
high-dose busulfan or TBI-based conventional MAC, compared
with RIC.5,10,28,29 Similarly, unfractionated or high-dose TBI
(⩾12 Gray),8 and/or a combination of busulfan and cyclo-
phosphamide lead to an increased incidence of SOS/VOD.8 Oral
busulfan may be replaced by i.v. busulfan, which is easier to
monitor, has a predictable pharmacokinetic proﬁle, and is
associated with a lower risk of SOS/VOD.30,31
Some drugs for GvHD prophylaxis have been reported to
increase the incidence of SOS/VOD. For instance, compared
Table 1. Risk factors for SOS/VOD
Transplant-related factors
Unrelated donor
HLA-mismatched donor
Non T-cell-depleted transplant
Myeloablative-conditioning regimen
Oral or high-dose busulfan-based regimen
High-dose TBI-based regimen
Second HCT
Patient and disease-related factors
Older age
Karnofsky score below 90%
Metabolic syndrome
Female receiving norethisterone
Advanced disease (beyond second CR or relapse/refractory)
Thalassemia
Genetic factors (GSTM1 polymorphism, C282Y allele, MTHFR
677CC/1298CC haplotype)
Hepatic-related
Transaminases 42.5 ULN
Serum bilirubin41.5 ULN
Cirrhosis
Active viral hepatitis
Abdominal or hepatic irradiation
Previous use of gemtuzumab ozogamicin or inotuzumab
ozogamicin
Hepatotoxic drugs
Iron overload
Abbreviations: SOS= sinusoidal obstruction syndrome; ULN= upper limit
of normal; VOD= veno-occlusive disease.
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with the combination of tacrolimus+sirolimus and tacrolimus
+methotrexate the combination of tacrolimus+sirolimus+
methotrexate after MAC TBI-based allo-HCT is associated with an
increased risk of SOS/VOD,32 leading the authors to conclude that
use of sirolimus is associated with SOS/VOD. Nevertheless,
preclinical data have shown that while sirolimus alone has no
effect, cyclosporine alone, tacrolimus alone and the combination
of tacrolimus+sirolimus, have a proinﬂammatory and prothrom-
botic effect on endothelial cells,33 suggesting it was the
association of sirolimus with another immunosuppressive therapy
and not sirolimus alone that contributed to endothelial cell
damage and, consequently, to SOS/VOD onset.33 Overall, the
effect of GvHD prophylaxis on endothelial cells probably depends
on concomitant treatments. At present, the available data are too
preliminary to conclusively identify a speciﬁc form of GvHD
prophylaxis as a SOS/VOD risk factor. Finally, second allo-HCT
should also be considered as a risk factor for SOS/VOD.10
Patient and disease-related factors
Reported patient-related risk factors for SOS/VOD are older age,
impaired Karnofsky status (o90) and metabolic syndrome.1,8,10 In
addition, an increased incidence of SOS/VOD has been reported in
women, but it was related to the use of norethisterone to prevent
gynecological bleeding.34 Genetic factors, such as GSTM1-null
genotype,35 the presence of the hemochromatosis C282Y allele,36
and the MTHFR 677CC/1298CC haplotype in patients receiving
MAC regimen with oral busulfan37 are associated with an
increased risk of SOS/VOD. This is also observed in patients with
advanced diseases (beyond CR2 or relapse) and in those with
thalassemia.1,8,10 Risk factors speciﬁc to the pediatric setting are
not discussed here (primarily hemophagocytic lymphohistio-
cytosis, osteopetrosis or thalassemia major, auto-HCT in patients
with neuroblastoma, younger age (under 1–2 years of age) and
low weight).1
Hepatic-related factors
Hepatic dysfunction before transplant, with increased levels of
bilirubin and transaminase, is one of the main risk factors of
SOS/VOD.8,17,38 This level of dysfunction can be found in
preexisting liver disease, such as cirrhosis, ﬁbrosis and active viral
hepatitis, or as a result of previous abdominal or hepatic
irradiation, or the use of hepatotoxic drugs such as gemtuzumab
ozogamicin or inotuzumab ozogamicin.8,17,39,40 Finally, elevated
ferritin level and iron overload are also considered as SOS/VOD
risk factors.41,42
BIOMARKERS AND IMAGING CRITERIA
Biomarker
The roles of endothelial cell injury and of microthrombus
formation in SOS/VOD pathophysiology have prompted investiga-
tions on their potential as biomarkers of the disease. Two studies
reported an elevated level of plasminogen activator inhibitor
(PAI-1) at diagnosis of SOS/VOD,43,44 and one group showed that,
besides its diagnostic value, PAI-1 levels may also be a prognostic
factor.45 Similarly, a decrease in protein C, alone46 or in
combination with a decrease of antithrombin III47 or of factor
VII,48 or an increase of tissue plasminogen activator and
N-terminal propeptide for type III procollagen49 before the onset
of SOS/VOD have been reported. As to the von Willebrand factor,
it was found to be increased in one study,48 but this was not
conﬁrmed in another.50 Cutler et al.51 reported that increased
levels of von Willebrand factor, thrombomodulin and soluble
intercellular adhesion molecule-I were predictive of SOS/VOD, but,
this result was limited to patients receiving sirolimus as GvHD
prophylaxis. Akil et al.52 used quantitative mass spectrometry-
based proteomic approach to identify candidate biomarkers by
comparing plasma pooled from 20 patients with and 20 without
SOS/VOD. Six candidate proteins identiﬁed by this approach and
ﬁve others selected from the literature were evaluated in samples
from 80 patients. Suppressor of tumorigenecity-2, angiopoietin-2,
L-ﬁcolin, hyaluronic acid and vascular cell adhesion molecule-1
(VCAM1) were found to be biomarkers for diagnosis of SOS/VOD.
Furthermore, L-ﬁcolin, hyaluronic acid and VCAM1 also stratiﬁed
patients at risk of SOS/VOD at day 0 of allo-HCT. Of note in that
study, the diagnostic role of PAI-1 and von Willebrand factor was
not conﬁrmed.52 Overall, the combined investigations produced
conﬂicting results, and none of these biomarkers is currently
routinely used. Given the complexity of allo-HCT techniques, the
hope to identify a biomarker valid in all settings is unlikely to be
successful.1 Therefore, further validation of these biomarkers in
the setting of a clinical trial is indispensable, after which, they may
be included in the criteria for diagnosis of SOS/VOD.
Imaging techniques
Imaging techniques have experienced major progress since the
1980s and the initial deﬁnition of the criteria for diagnosis of
SOS/VOD,3,4 raising the possibility that they may contribute to
reﬁning such diagnosis today. The role of ultrasound has been
investigated in several studies, but most of them were published
almost two decades ago, with conﬂicting results, as reviewed by
Mahgerefteh et al.53 The reported abnormalities in SOS/VOD
are not speciﬁc, and included hepatomegaly, splenomegaly,
gallbladder wall thickening, ascites and portal venous ﬂow
abnormalities.53,54 The latter—decrease in velocity or reversal of
the portal venous ﬂow—are considered more speciﬁc for
SOS/VOD, but usually occur late in the disease,53–55 and their
interest for SOS/VOD early diagnosis is limited.
Measurement of the hepatic venous gradient pressure through
the jugular vein is the most accurate method to conﬁrm the
diagnosis of SOS/VOD.24,56,57 However, this technique is invasive,
requires an expert hemodynamist, and is not routinely available in
most centers. Therefore, doppler ultrasonography has been
investigated to evaluate changes in portal circulation. Although
the correlation between hepatic arterial resistive indices and
portal hypertension is controversial, the hepatic arterial early
acceleration index correlated directly with Hepatic venous
pressure gradient.58 Nevertheless, although non-invasive, this
technique requires expert echographers, and is not available in
most centers.
Few studies, mostly case reports, investigate the role of other
imaging techniques.23 Periportal edema, ascites and a narrow
right hepatic vein on computerized tomography scans are
suggestive of SOS/VOD.59,60 Similarly, magnetic resonance
imaging scans of patients with SOS/VOD have detected hepato-
megaly, ascites, hepatic vein narrowing, gallbladder wall
thickening, peri-portal cufﬁng or patchy signal enhancement of
the liver.59,61–64 Of note, a high speciﬁcity of supramagnetic iron
oxide-enhanced magnetic resonance imaging and gadoteric
acid-enhanced magnetic resonance imaging for SOS/VOD
diagnosis in patients with chemotherapy-treated colorectal liver
metastases has been reported,65,66 but these imaging modalities
have not been evaluated in the setting of HCT.
At present, the role of imaging in SOS/VOD remains limited to
ultrasound to assist in the exclusion of differential diagnoses. In
addition, ultrasound may be helpful to conﬁrm clinical ﬁndings
such as hepatomegaly and ascites, which can be difﬁcult to assess
in particular in overweight patients. Baseline and serial ultrasound
measurements may be useful for early detection of signs
suggestive of SOS/VOD, although daily clinical examination and
weight monitoring remain the gold standards. Prospective
evaluation of hepatic arterial early acceleration index and of
supramagnetic iron oxide- or gadoteric acid-enhanced magnetic
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resonance imaging for SOS/VOD monitoring/diagnosis seems
indispensable before recommending their use and integration
into the SOS/VOD diagnostic criteria.
NEW EBMT CRITERIA FOR DIAGNOSIS OF SOS/VOD
The updated EBMT criteria for diagnosis of SOS/VOD in adult
patients are given in Table 2. The supporting data for each of the
changes are discussed below.
Symptoms of SOS/VOD are typically observed within the ﬁrst
weeks after HCT, and both modiﬁed Seattle17 and Baltimore4
criteria require that patients must be within 21 days after HCT to
make the diagnosis of this complication. However, late onset
SOS/VOD beyond day 21 has been reported.7 The investigators
thus recommend including late onset SOS/VOD (beyond day 21)
in these clinical criteria.
Carreras et al.24,67 reported that haemodynamic studies could
not conﬁrm the diagnosis of SOS/VOD diagnosis in 42% of adult
patients with only two clinical manifestations listed in the Seattle
criteria, compared with only 9% using the Baltimore criteria. The
main difference between the two classiﬁcations is hyperbilirubi-
nemia, mandatory in the Baltimore, but not in the modiﬁed Seattle
criteria. Hyperbilirubinemia and jaundice are rarely absent in
adults with classical SOS/VOD, but can be absent in SOS/VOD that
develops later.24 Therefore, most groups treating adult patients
prefer to use the Baltimore criteria, including in the setting of
prospective clinical trials.11 Therefore, for classical SOS/VOD, which
occurs within the ﬁrst 21 days after HCT, and despite the fact that
hyperbilirubinemia can be a delayed manifestation in SOS/VOD
(occurring lately after liver pain and ﬂuid retention), the group
decided to keep using the Baltimore criteria.
Beyond day 21, the Baltimore criteria are still valid to establish
the diagnosis of SOS/VOD. However, this may represent a problem
in patients who develop late onset SOS/VOD in the absence
of hyperbilirubinemia, with only weight gain and ascites.6,7,24
Therefore, hyperbilirubinemia should no longer be mandatory in
late onset SOS/VOD, and the diagnosis of late onset SOS/VOD may
be made if patients fulﬁll a less stringent version of the Baltimore
criteria, that is, at least two of the following: bilirubin ⩾ 2 mg/dL,
painful hepatomegaly, weight gain45% or ascites. However,
hemodynamic and/or ultrasound evidence of SOS/VOD
(hepatomegaly, ascites and decrease in velocity or reversal of
the portal ﬂow) is mandatory in addition to these criteria. Finally,
although transjugular liver biopsy is invasive and difﬁcult to
perform, histological evidence of SOS/VOD remains the gold
standard (but not mandatory) for the diagnosis.56,57
Obviously, many other causes can also lead to liver dysfunction
after HCT, such as hepatic GvHD, viral infection, iron
overload, sepsis and drug toxicity. Patient history, concomitant
symptoms and laboratory testing allow exclusion of these
differential diagnoses. However, one must keep in mind that
SOS/VOD may coexist with others conditions presenting common
symptoms.
Peripheral thrombocytopenia with a rapid consumption of
transfused platelets is frequently observed in patients with
SOS/VOD,24,68 and it has been debated whether it should be
included as a diagnostic criterion. However, this feature is difﬁcult
to evaluate during the pancytopenic phase after conditioning,24
and lack speciﬁcity, given the numerous causes of thrombocyto-
penia after HCT. Therefore thrombocytopenia with rapid platelet
consumption was not retained as a criterion for SOS/VOD
diagnosis.
Table 2. New EBMT criteria for SOS/VOD diagnosis in adults
Classical SOS/VOD
In the ﬁrst 21 days after HSCT
Late onset SOS/VOD
421 Days after HSCT
Bilirubin ⩾ 2 mg/dL and two
of the following criteria must
be present:
Classical VOD/SOS beyond day 21
OR
Painful hepatomegaly Histologically proven SOS/VOD
Weight gain 45% OR
Ascites Two or more of the following criteria
must be present:
Bilirubin ⩾ 2 mg/dL (or 34 μmol/L)
Painful hepatomegaly
Weight gain45%
Ascites
AND Hemodynamical or/and
ultrasound evidence of SOS/VOD
Abbreviations: EBMT= European Society for Blood and Marrow Transplan-
tation; SOS= sinusoidal obstruction syndrome; VOD= veno-occlusive
disease. These symptoms/signs should not be attributable to other causes.
Table 3. New EBMT criteria for severity grading of a suspected SOS/VOD in adults
Milda Moderatea Severe Very severe - MOD/MOFb
Time since ﬁrst clinical
symptoms of SOS/VODc
47 Days 5–7 Days ⩽ 4 Days Any time
Bilirubin (mg/dL) ⩾ 2 and o3 ⩾ 3 ando5 ⩾ 5 ando8 ⩾ 8
Bilirubin (μmol/L) ⩾ 34 and o51 ⩾ 51 ando85 ⩾ 85 and o136 ⩾ 136
Bilirubin kinetics Doubling within 48 h
Transaminases ⩽ 2 × normal 4 2 and⩽ 5 × normal 45 and ⩽ 8 × normal 48×Normal
Weight increase o 5% ⩾ 5% and o10% ⩾ 5% and o10% ⩾ 10%
Renal function o1.2 ×
baseline at transplant
⩾ 1.2 ando1.5 ×
baseline at transplant
⩾ 1.5 and o2 ×
baseline at transplant
⩾ 2 ×
baseline at transplant or
others signs of MOD/MOF
Abbreviations: EBMT= European society for Blood and Marrow Transplantation; MOD=multi-organ dysfunction; MOF=multi-organ failure; SOS= sinusoidal
obstruction syndrome; VOD= veno-occlusive disease. Patients belong to the category that fulﬁlls two or more criteria. If patients fulﬁll two or more criteria in
two different categories, they must be classiﬁed in the most severe category. Patients weight increase ⩾ 5% and o10% is considered by default as a criterion
for severe SOS/VOD; however, if patients do not fulﬁll other criteria for severe SOS/VOD, weight increase ⩾ 5% and o10% is therefore considered as a criterion
for moderate SOS/VOD. aIn the case of presence of two or more risk factors for SOS/VOD, patients should be in the upper grade. bPatients with multi-organ
dysfunction must be classiﬁed as very severe. cTime from the date when the ﬁrst signs/symptoms of SOS/VOD began to appear (retrospectively determined)
and the date when the symptoms fulﬁlled SOS/VOD diagnostic criteria.
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NEW EBMT CRITERIA FOR SEVERITY GRADING OF SUSPECTED
SOS/VOD IN ADULTS
Currently, once the diagnosis of SOS/VOD is established, we lack a
score to truly assess its severity, and to identify patients requiring
early therapeutic intervention. This is particularly relevant, since
treatment options are available, and data show that early
intervention is justiﬁable.69 Bearman et al.70 attempted to develop
a logistic regression model to estimate probabilities of severe
SOS/VOD at different time points after MAC allo-HCT. In that
model, early serum bilirubin and weight gain can estimate 50% or
higher probability of developing severe SOS/VOD. However, the
model was helpful in only a minority of patients who developed
severe SOS/VOD within the ﬁrst 16 days after a MAC allo-HCT.70
More recently, the concept of SOS/VOD grade based on
measurable clinical data has been introduced.24,71
We propose new EBMT criteria for grading SOS/VOD severity in
adult patients and to guide therapy decisions, based on the level
of bilirubin and its rate of change, liver function (transaminase),
weight increase, renal function and the kinetic of their onset
(Table 3). This grading system is divided into ﬁve categories,
as in the Common Terminology Criteria for Adverse Events: grade
1 =mild; grade 2 =moderate; grade 3 = severe; grade 4 = very
severe; and grade 5 =death.
It is well established that serum bilirubin levels increase with the
severity of SOS/VOD.17,24,70,72 Therefore, serum bilirubin level
cutoff points have been deﬁned to reﬂect this correlation. In
addition, particular emphasis is placed on the rate of increase of
serum bilirubin. Indeed, the risk of developing a severe SOS/VOD
in a patient whose serum bilirubin level increases from 3 to
6 mg/dL within 48 h is higher than that of a patient who reaches
this level over a longer period.17,72 Therefore, we decided to take
into account the bilirubin kinetics in our grading system. A serum
level doubling within 48 h is a criterion for classiﬁcation of
SOS/VOD as severe (for example, a bilirubin increase from 3 to
6 mg/dL within 48 h is sufﬁcient to classify the SOS/VOD as
severe). However, attention must be paid to other possible causes
of rapid increase of serum bilirubin level, before retaining this
criterion. Of note, bilirubin level and kinetics are not exclusive.
Like serum bilirubin, liver dysfunction increases with the
severity of SOS/VOD.24 As the levels of transaminases appear to
be the most relevant parameter to evaluate liver dysfunction,
cutoff points have also been deﬁned to reﬂect this correlation.
Weight increase is part of the diagnostic criteria of SOS/VOD
and also reﬂects the development of ascites. Weight gain is
directly correlated with the severity of the pathophysiological
process at play in SOS/VOD.1,38,70 Therefore, it appears to be a
relevant parameter for evaluation of SOS/VOD severity. A weight
gain of more than 5 or 10% will be a criterion to classify SOS/VOD
as moderate/severe or very severe, respectively. Given the
difﬁculty in practice to objectively assess a little variation in
weight, we decided not to deﬁne a weight gain threshold for
distinguishing mild SOS/VOD. Of note, weight increase must be
assessed when patients have received an optimal diuretic
treatment.
Post-sinusoidal portal hypertension and volume loss in the third
space (edema, ascites) leads to hypovolemia and to renal failure.
The association between severity of SOS/VOD and renal failure has
been reported in numerous studies.17,73–76 In order to grade the
latter, creatinemia cutoff points have been deﬁned in our
criteria set.
The kinetics of appearance of the symptoms are also of major
importance to evaluate the severity of SOS/VOD. A patient whose
symptoms emerge within days, is much more likely to develop a
severe SOS/VOD, than one whose symptoms emerge over a
period 47 days.24,38,70 Therefore, a criterion evaluating the time
from the date when the ﬁrst signs of SOS/VOD began to appear
(retrospectively determined) and the date when the diagnosis of
SOS/VOD is effectively performed has been introduced in our
grading system.
Patients belong to the category that fulﬁlls two or more criteria
(bilirubin level, bilirubin kinetics, liver function, weight increase,
renal function and symptom kinetics). If a patient fulﬁlls two or
more criteria in two different categories, he/she must be classiﬁed
in the most severe category. In addition, patients with MOD/MOF
will be systematically classiﬁed as very severe.5,11–13,24 This is
deﬁned as a clinical syndrome characterized by the development
of progressive and potentially reversible physiologic dysfunction
in two or more organs.77 Within the proposed new EBMT criteria,
renal failure is deﬁned as creatinemia ⩾ 2 times the baseline at
transplant, or creatinine clearance ⩽ 50% level at transplant, or
dialysis; pulmonary failure as oxygen saturation ⩽ 90% on room air
and/or the need for positive pressure/ventilator dependence not
attributable to any other cause; central nervous system failure as
confusion, lethargy and/or delirium not attributable to any other
cause.24
In addition, particular attention should be paid to the number of
SOS/VOD risk factors. The risk of developing a severe form of the
disease may increase with the number of risk factors. Therefore,
we suggest that, in the presence of two or more risk factors, mild
SOS/VOD should be classiﬁed as moderate and moderate SOS/
VOD as severe. This is particularly important since it may allow
earlier treatment in patients with multiple SOS/VOD risk factors.
Finally these new EBMT criteria for severity grading of SOS/VOD
may be used for suspected SOS/VOD, before patients fulﬁll the
diagnostic criteria, especially before day 21. It may allow early
therapeutic intervention in patients with severe or very severe
suspected SOS/VOD that do not fulﬁll yet SOS/VOD diagnostic
criteria.
CONCLUSION
By deﬁning these new EBMT diagnostic and severity criteria for
SOS/VOD, we aimed at overcoming the lack of speciﬁcity and
sensitivity of the current criteria. We acknowledge that our
proposal must be ideally prospectively validated in clinical studies.
Furthermore, these criteria may not be deﬁnitive, as lack of
validated biomarkers and of validation/expertise in new imaging
modalities prevented us from incorporating them into the new
classiﬁcation. We believe that the new EBMT severity-grading
criteria could be a valuable tool to accurately assess the severity of
the condition at diagnosis, rather than only retrospectively.
Altogether, our proposed diagnostic and severity-grading criteria,
when validated in prospective studies, will allow an earlier
identiﬁcation and quantiﬁcation of SOS/VOD, aiding in the
selection of patients requiring immediate therapeutic
intervention.
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